[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Propofol.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Propofol.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Propofol.]
[J01EC02, sulfadiazine, The metabolism of Propofol can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Propofol can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Propofol is combined with Sulfamethoxazole.]
[J01EC03, sulfamoxole, The metabolism of Propofol can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Propofol can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Propofol can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Propofol can be decreased when combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Propofol.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Propofol.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Propofol is combined with Sulthiame.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Propofol.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Propofol is combined with Azapropazone.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Propofol.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Propofol.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Propofol.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Propofol.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Propofol is combined with Terbutaline.]
[G03BA03, testosterone, The metabolism of Propofol can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of sedation and somnolence can be increased when Propofol is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Propofol is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Propofol is combined with Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Propofol.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Propofol.]
[L04AX02, thalidomide, Propofol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Propofol.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Eribulin.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Propofol.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Propofol.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Propofol.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Propofol is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Propofol is combined with Thiothixene.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Propofol is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Propofol is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Propofol can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Propofol is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Propofol.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Propofol.]
[M02AX02, tolazoline, Propofol may decrease the antihypertensive activities of Tolazoline.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Propofol.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Propofol.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Propofol is combined with Tolperisone.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Propofol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Propofol.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Propofol.]
[L01XF01, tretinoin, The metabolism of Propofol can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Propofol.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Propofol.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Propofol is combined with Triazolam.]
[C03AA06, trichlormethiazide, Propofol may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Propofol may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Propofol is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Propofol is combined with Trifluperidol.]
[N05AA05, triflupromazine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Propofol may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Propofol can be decreased when combined with Mometasone.]
[A03AA05, trimebutine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Propofol is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Propofol.]
[C02BA01, trimethaphan, Propofol may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Propofol can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Propofol.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Propofol.]
[A03BB01, butylscopolamine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Propofol is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Propofol.]
[C09CA09, azilsartan medoxomil, Propofol may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Propofol is combined with Tubocurarine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Propofol.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Propofol.]
[L02BX03, abiraterone, The metabolism of Propofol can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be decreased when combined with Propofol.]
[J05AG05, rilpivirine, The metabolism of Propofol can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Propofol is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Indacaterol.]
[B01AC24, ticagrelor, The metabolism of Propofol can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Propofol can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Propofol is combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Propofol.]
[C04AX07, vincamine, Propofol may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Propofol.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Propofol.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Propofol.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Fusidic acid.]
[N01AX15, xenon, The therapeutic efficacy of Xenon can be increased when used in combination with Propofol.]
[C03BA10, xipamide, Propofol may decrease the antihypertensive activities of Xipamide.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Propofol is combined with Pipemidic acid.]
[J05AF01, zidovudine, The metabolism of Propofol can be increased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Zuclopenthixol.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Propofol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Propofol is combined with Levetiracetam.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Propofol.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Propofol.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Propofol.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Propofol.]
[R03DC01, zafirlukast, The metabolism of Propofol can be decreased when combined with Zafirlukast.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propofol.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Propofol is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Propofol.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Propofol is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Propofol.]
[G04BD07, tolterodine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Propofol may decrease the antihypertensive activities of Atenolol.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Propofol.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Propofol is combined with Atracurium.]
[S01FA01, atropine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Propofol.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Propofol.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Propofol.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Propofol.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Propofol is combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Propofol is combined with Mirabegron.]
[J05AJ02, elvitegravir, The metabolism of Elvitegravir can be decreased when combined with Propofol.]
[L02BB04, enzalutamide, The serum concentration of Propofol can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Propofol.]
[L04AA31, teriflunomide, The metabolism of Propofol can be decreased when combined with Teriflunomide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Propofol is combined with Octopamine.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Propofol.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Propofol.]
[J05AE04, nelfinavir, The metabolism of Propofol can be increased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Propofol.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Propofol.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Propofol.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Propofol is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Propofol is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Propofol.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Propofol.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Propofol.]
[R06AC06, thonzylamine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Propofol may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AB02, chloroform, The therapeutic efficacy of Chloroform can be increased when used in combination with Propofol.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Propofol is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Propofol can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Propofol is combined with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Propofol.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Propofol.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Propofol.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Propofol.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Propofol is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Propofol is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, Propofol may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Propofol.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Propofol.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Propofol is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Propofol is combined with Benperidol.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Propofol is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Propofol can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Propofol can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Propofol is combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Propofol can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Propofol is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Propofol.]
[N04AC01, benztropine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Propofol can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Propofol is combined with Benzydamine.]
[L01EE01, trametinib, The metabolism of Propofol can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Propofol is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Propofol is combined with Levomilnacipran.]
[J05AJ03, dolutegravir, The metabolism of Dolutegravir can be decreased when combined with Propofol.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Propofol is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Propofol.]
[G03XC02, bazedoxifene, The metabolism of Bazedoxifene can be decreased when combined with Propofol.]
[C02KX04, macitentan, Propofol may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Propofol.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Propofol is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Propofol is combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Propofol is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Propofol is combined with Dapagliflozin.]
[C01CA27, droxidopa, The risk or severity of hypertension can be increased when Propofol is combined with Droxidopa.]
[C07AB04, acebutolol, Propofol may decrease the antihypertensive activities of Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Propofol is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Propofol can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Propofol.]
[S01ED02, betaxolol, Propofol may decrease the antihypertensive activities of Betaxolol.]
[C02CC01, bethanidine, Propofol may decrease the antihypertensive activities of Bethanidine.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Propofol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Propofol.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Propofol.]
[A03BA03, hyoscyamine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Propofol.]
[L01XH04, belinostat, The metabolism of Belinostat can be decreased when combined with Propofol.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Propofol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Propofol is combined with Alfaxalone.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Propofol is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Olodaterol.]
[D11AA01, glycopyrronium, Propofol may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Propofol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Propofol.]
[J01XA05, oritavancin, The metabolism of Propofol can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Propofol is combined with Acepromazine.]
[N04AA02, biperiden, Propofol may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Propofol.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Propofol.]
[J05AP09, dasabuvir, The metabolism of Propofol can be decreased when combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Propofol.]
[B01AA01, dicumarol, The metabolism of Propofol can be decreased when combined with Dicoumarol.]
[N06AX11, mirtazapine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Propofol can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Propofol.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Propofol is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Propofol.]
[N02BE01, acetaminophen, Propofol may increase the hepatotoxic activities of Acetaminophen.]
[A03AA09, difemerine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Propofol.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Propofol is combined with Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Propofol.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Propofol is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Propofol is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Propofol is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Propofol is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Propofol is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Propofol is combined with Acetophenazine.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Acipimox.]
[A02BC03, lansoprazole, The metabolism of Propofol can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Propofol.]
[J02AC05, isavuconazole, The metabolism of Propofol can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Propofol.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Propofol.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Propofol.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Propofol.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Propofol.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Propofol.]
[A10BB31, acetohexamide, The metabolism of Propofol can be decreased when combined with Acetohexamide.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Propofol.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Propofol.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Propofol is combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Propofol is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Propofol is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Propofol.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Propofol is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Propofol is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propofol.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Propofol is combined with Amineptine.]
[C08CA01, amlodipine, Propofol may decrease the antihypertensive activities of Amlodipine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Propofol.]
[N01AH05, anileridine, The therapeutic efficacy of Anileridine can be increased when used in combination with Propofol.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Propofol is combined with Aniracetam.]
[C03CA02, bumetanide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Propofol.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Bupranolol.]
[N07BC01, buprenorphine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Propofol.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Propofol.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Propofol is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Propofol is combined with Artemether.]
[N02AF01, butorphanol, Butorphanol may increase the sedative activities of Propofol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Propofol.]
[S01GX07, azelastine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Propofol can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Propofol.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Propofol is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Propofol is combined with Bambuterol.]
[N07XX16, deutetrabenazine, The risk or severity of sedation and somnolence can be increased when Propofol is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Propofol can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Propofol is combined with Beclamide.]
[C09AA07, benazepril, Propofol may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Propofol is combined with Oxybuprocaine.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Propofol.]
[J05AF06, abacavir, The metabolism of Abacavir can be decreased when combined with Propofol.]
[J05AE09, tipranavir, The metabolism of Propofol can be increased when combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Propofol can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Propofol.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Propofol.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Propofol.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Delafloxacin.]
[L01BC06, capecitabine, The metabolism of Propofol can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Propofol.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Propofol.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Propofol is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Propofol.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Propofol.]
[C07AB07, bisoprolol, Propofol may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Propofol is combined with Bitolterol.]
[J05AG03, efavirenz, The metabolism of Propofol can be increased when combined with Efavirenz.]
[N04AA11, bornaprine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Propofol is combined with Nesiritide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Propofol is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Propofol is combined with Brotizolam.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Propofol is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Propofol is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Propofol.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Propofol is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Propofol.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Propofol is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Propofol is combined with Acetyldigoxin.]
[A10BK04, ertugliflozin, The metabolism of Propofol can be decreased when combined with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Propofol is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Apalutamide can be decreased when combined with Propofol.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Propofol.]
[A03AA03, camylofine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Propofol.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Propofol.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Propofol.]
[B02BX09, fostamatinib, The metabolism of Propofol can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Propofol.]
[B02BX08, avatrombopag, The metabolism of Propofol can be increased when combined with Avatrombopag.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Propofol is combined with Encorafenib.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Propofol.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Propofol.]
[L01XX62, ivosidenib, The metabolism of Propofol can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, The metabolism of Migalastat can be decreased when combined with Propofol.]
[N03AX17, stiripentol, The metabolism of Propofol can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Propofol can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Propofol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Propofol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Propofol.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Propofol is combined with Carbromal.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Propofol.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Propofol is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Propofol is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Propofol is combined with Inotersen.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Propofol.]
[R03BB08, revefenacin, Propofol may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Propofol can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Propofol is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Propofol is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Propofol is combined with Amifampridine.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Propofol.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Propofol is combined with Cibenzoline.]
[C09AA08, cilazapril, Propofol may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Propofol.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Propofol is combined with Cinitapride.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Propofol is combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Propofol.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Propofol.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Propofol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Propofol is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Propofol.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Propofol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Propofol is combined with Cloxazolam.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Ubidecarenone.]
[C09CA06, candesartan, The metabolism of Propofol can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Propofol can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The serum concentration of Propofol can be decreased when it is combined with Alpelisib.]
[L02BB06, darolutamide, The metabolism of Darolutamide can be decreased when combined with Propofol.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Propofol.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Propofol is combined with Cyamemazine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Propofol.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Propofol is combined with Entrectinib.]
[N07XX11, pitolisant, Propofol may increase the QTc-prolonging activities of Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Propofol.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Propofol.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Propofol.]
[C03AA09, cyclothiazide, Propofol may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Propofol is combined with Yohimbine.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propofol.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Propofol.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Propofol.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Propofol.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Propofol.]
[G03AC09, desogestrel, The metabolism of Propofol can be increased when combined with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Propofol.]
[N03AX25, cenobamate, The serum concentration of Propofol can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Propofol.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propofol.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Dexchlorpheniramine.]
[N02AX03, dezocine, Dezocine may increase the sedative activities of Propofol.]
[L01EX18, avapritinib, The metabolism of Propofol can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, The serum concentration of Propofol can be decreased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Propofol.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Propofol.]
[M01AX21, diacetylrhein, The metabolism of Propofol can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Osilodrostat can be decreased when combined with Propofol.]
[J05AE05, amprenavir, The metabolism of Propofol can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Propofol is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Propofol is combined with Dutasteride.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Propofol.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Propofol is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Propofol.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Propofol is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Propofol is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Propofol.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Propofol.]
[L01XF03, bexarotene, The metabolism of Propofol can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Propofol can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Propofol.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Propofol is combined with Valpromide.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Chlorcyclizine.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Propofol.]
[C02AA06, methoserpidine, Propofol may decrease the antihypertensive activities of Methoserpidine.]
[L01FX17, sacituzumab govitecan, The serum concentration of Sacituzumab govitecan can be increased when it is combined with Propofol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Propofol.]
[A03AA08, dihexyverine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Propofol is combined with Opicapone.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Propofol is combined with Dopexamine.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Propofol.]
[G04BD09, trospium, Propofol may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Propofol is combined with Droxicam.]
[L01EX22, selpercatinib, The serum concentration of Propofol can be increased when it is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Propofol is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Propofol is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Propofol is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Propofol.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Propofol.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Propofol is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Propofol.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Propofol is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Propofol can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Propofol is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Propofol.]
[L01EX23, pralsetinib, The metabolism of Propofol can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Propofol may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Propofol is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Propofol can be decreased when combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Propofol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Propofol may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Propofol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Propofol is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Propofol is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Propofol is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Propofol is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Propofol.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Propofol is combined with Etofenamate.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Etofibrate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Propofol is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be decreased when combined with Propofol.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Propofol is combined with Relugolix.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Propofol is combined with Naxitamab.]
[J05AJ04, cabotegravir, The metabolism of Cabotegravir can be decreased when combined with Propofol.]
[P03AX07, abametapir, The serum concentration of Propofol can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Propofol is combined with Vericiguat.]
[L01EX21, tepotinib, The metabolism of Propofol can be decreased when combined with Tepotinib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Propofol is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Propofol is combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Propofol is combined with Fenbufen.]
[C01CA19, fenoldopam, Propofol may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Propofol is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Propofol is combined with Finasteride.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Flumequine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Propofol.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Propofol is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Propofol can be increased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Propofol may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Propofol.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Propofol is combined with Gabapentin.]
[N07CA02, cinnarizine, The metabolism of Propofol can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Cinoxacin.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Propofol.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Propofol.]
[L01XA01, cisplatin, The metabolism of Propofol can be decreased when combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Propofol is combined with Citalopram.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Propofol.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Propofol is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Propofol is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Propofol can be decreased when combined with Mefenamic acid.]
[A10BB12, glimepiride, The metabolism of Propofol can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Propofol.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Propofol is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Propofol is combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Propofol can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Propofol.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Propofol.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Clofazimine.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Propofol.]
[B06AX04, mitapivat, The metabolism of Propofol can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Propofol is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Propofol is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Propofol.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Propofol.]
[C01EB24, mavacamten, The serum concentration of Propofol can be decreased when it is combined with Mavacamten.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Propofol is combined with Clothiapine.]
[H01CC04, linzagolix, The serum concentration of Propofol can be increased when it is combined with Linzagolix.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Propofol is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Propofol is combined with Granisetron.]
[N05AH02, clozapine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Propofol.]
[S02DA02, cocaine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Propofol may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Propofol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Propofol is combined with Proquazone.]
[R05DA04, codeine, Codeine may increase the sedative activities of Propofol.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Propofol is combined with Hexafluronium.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Propofol.]
[A03AB10, hexocyclium, Propofol may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Propofol may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Propofol is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Propofol is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Propofol is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Propofol can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Propofol is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Propofol is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Propofol is combined with Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Propofol.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Propofol is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Propofol is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Propofol is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Propofol can be decreased when combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Emedastine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Propofol is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Propofol is combined with Kebuzone.]
[L02BA03, fulvestrant, The metabolism of Fulvestrant can be decreased when combined with Propofol.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Propofol is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Propofol is combined with Posaconazole.]
[C08CA09, lacidipine, Propofol may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, The metabolism of Propofol can be increased when combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Levocabastine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Propofol.]
[N07BC04, lofexidine, The therapeutic efficacy of Propofol can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Propofol is combined with Lonazolac.]
[R06AX13, loratadine, The metabolism of Propofol can be decreased when combined with Loratadine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Propofol is combined with Loxoprofen.]
[C09AA03, lisinopril, Propofol may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Propofol can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Propofol is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Propofol is combined with Mefenorex.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Adenosine.]
[N04AA03, methixene, Propofol may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Propofol is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Propofol is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Propofol is combined with Cyclobarbital.]
[C03DA04, eplerenone, Propofol may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Propofol is combined with Melperone.]
[C03AA07, cyclopenthiazide, Propofol may decrease the antihypertensive activities of Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Propofol.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Propofol.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Propofol.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Propofol.]
[N06BA07, modafinil, The metabolism of Propofol can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Propofol.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Propofol is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Propofol is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Propofol.]
[C02AC05, moxonidine, Propofol may decrease the antihypertensive activities of Moxonidine.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Cytarabine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Propofol.]
[M01AH05, etoricoxib, The metabolism of Propofol can be decreased when combined with Etoricoxib.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Propofol is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Propofol can be decreased when combined with Dapsone.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Propofol is combined with Deanol.]
[C02CC04, debrisoquin, Propofol may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Propofol.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Propofol.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Nordazepam.]
[C07AB12, nebivolol, Propofol may decrease the antihypertensive activities of Nebivolol.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Propofol is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Propofol is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Propofol.]
[L02BB02, nilutamide, The metabolism of Propofol can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Propofol is combined with Tiagabine.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Propofol is combined with Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Propofol.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Propofol is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Propofol is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Propofol is combined with Escitalopram.]
[G04BD08, solifenacin, Propofol may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Propofol is combined with Olsalazine.]
[N06AA01, desipramine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Propofol.]
[C09XA02, aliskiren, Propofol may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Propofol is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Propofol.]
[S03BA01, dexamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Propofol is combined with Oxiracetam.]
[N04AA08, dexetimide, Propofol may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Propofol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Propofol can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Propofol.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Propofol.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Propofol.]
[N02AC01, dextromoramide, Dextromoramide may increase the sedative activities of Propofol.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Propofol is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Propofol can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, Diamorphine may increase the sedative activities of Propofol.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Propofol is combined with Phenacemide.]
[V03AH01, diazoxide, Propofol may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Propofol is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Propofol is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Propofol.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Propofol is combined with Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Propofol.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Propofol.]
[A03AA07, dicyclomine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, Propofol may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Propofol is combined with Pinaverium.]
[A10BG03, pioglitazone, The metabolism of Propofol can be decreased when combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Propofol is combined with Pipamperone.]
[A03AB14, pipenzolate, Propofol may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Propofol.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Propofol.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Propofol is combined with Pirbuterol.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Propofol is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Propofol can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Propofol.]
[A03AB11, poldine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The metabolism of Propofol can be decreased when combined with Diflunisal.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Propofol.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Propofol.]
[C02DB01, dihydralazine, Propofol may decrease the antihypertensive activities of Dihydralazine.]
[C10AX09, ezetimibe, The metabolism of Ezetimibe can be decreased when combined with Propofol.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Propofol is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Propofol.]
[N02AA03, hydromorphone, Hydromorphone may increase the sedative activities of Propofol.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Propofol is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Propofol.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Propofol is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Propofol can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Propofol is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Propofol is combined with Pridinol.]
[R06AB03, dimethindene, Propofol may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Propofol is combined with Procaterol.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Propofol is combined with Progabide.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Propofol is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Propofol is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Propofol can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Propofol is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Quazepam.]
[C09AA06, quinapril, Propofol may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Propofol is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Propofol is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Propofol is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Propofol is combined with Cisapride.]
[C09AA05, ramipril, Propofol may decrease the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Propofol.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Propofol.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Propofol is combined with Reproterol.]
[C01BA03, disopyramide, Propofol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Propofol is combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Propofol can be decreased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Propofol can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Propofol.]
[N05AX08, risperidone, Propofol may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Propofol is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Propofol.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Propofol.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Propofol.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Propofol.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Propofol.]
[G04BE08, tadalafil, Propofol may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The metabolism of Propofol can be decreased when combined with Ketorolac.]
[C02KX02, ambrisentan, Propofol may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Propofol is combined with Salsalate.]
[R03AC12, salmeterol, The metabolism of Propofol can be decreased when combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Propofol is combined with Dobutamine.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Propofol is combined with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Propofol is combined with Dopamine.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Propofol.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Propofol.]
[N06AA12, doxepin, Propofol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Propofol.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Propofol.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Propofol is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Propofol is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Propofol.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Propofol is combined with Sibutramine.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Propofol.]
[C09AA11, spirapril, Propofol may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Propofol is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Propofol.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Propofol.]
[G04CA03, terazosin, Propofol may decrease the antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Propofol is combined with Terodiline.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Propofol is combined with Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Propofol is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Propofol is combined with Thiopropazate.]
[G04BD01, emepronium, Propofol may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Emetine.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Propofol.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Propofol.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Propofol is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Propofol is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Propofol.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Propofol.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Propofol.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Propofol is combined with Toremifene.]
[C03CA04, torsemide, The metabolism of Propofol can be decreased when combined with Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Propofol is combined with Tramazoline.]
[C09AA10, trandolapril, Propofol may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Propofol is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Propofol is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Propofol is combined with Triclofos.]
[A03AB08, tridihexethyl, Propofol may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Propofol.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Triptorelin.]
[N04AA12, tropatepine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Propofol is combined with Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Propofol.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Propofol is combined with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Propofol.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Propofol is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Propofol.]
[S01FB02, ephedrine, Propofol may increase the hypertensive activities of Ephedrine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Propofol.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Propofol.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Propofol is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Propofol is combined with Xylometazoline.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Propofol is combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Propofol can be decreased when combined with Epinephrine.]
[C09AA15, zofenopril, Propofol may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Propofol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Propofol is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Propofol is combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Propofol.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Propofol is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Propofol is combined with Guanfacine.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Propofol.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Propofol is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Propofol is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Propofol.]
[N03AG01, valproic acid, The serum concentration of Propofol can be increased when it is combined with Valproic acid.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Propofol is combined with Estazolam.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Propofol.]
[J04AK02, ethambutol, The metabolism of Propofol can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Propofol can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Propofol can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Propofol can be decreased when combined with Fluvastatin.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Propofol is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propofol.]
[L02AA03, ethinyl estradiol, The metabolism of Propofol can be increased when combined with Ethinylestradiol.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Propofol is combined with Amifostine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Propofol is combined with Ibutilide.]
[N04AA05, profenamine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Propofol.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Propofol.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Propofol.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Propofol is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Propofol is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Propofol.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Propofol.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Propofol is combined with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Propofol is combined with Ajmaline.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Propofol.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Propofol.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Propofol.]
[R06AX12, terfenadine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Propofol.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Propofol is combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Propofol is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Propofol.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Propofol.]
[M01CB01, gold sodium thiomalate, The metabolism of Propofol can be decreased when combined with Sodium aurothiomalate.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Propofol.]
[C08CA02, felodipine, The metabolism of Propofol can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Propofol is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Propofol.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Propofol.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Propofol is combined with Fenoterol.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Propofol.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Salbutamol.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Propofol.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Propofol.]
[G04BD02, flavoxate, Propofol may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Propofol can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Propofol is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Propofol can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Propofol is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Propofol is combined with Melitracen.]
[V03AZ01, ethanol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Propofol can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Propofol.]
[N06AB03, fluoxetine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Flupentixol may increase the sedative activities of Propofol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Propofol.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Propofol.]
[S01BC04, flurbiprofen, The metabolism of Propofol can be decreased when combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Propofol is combined with Fluspirilene.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Propofol.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Propofol is combined with Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Propofol is combined with Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Propofol.]
[C03CA01, furosemide, The metabolism of Furosemide can be decreased when combined with Propofol.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Propofol.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Propofol is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Propofol is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Propofol.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Propofol is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Propofol is combined with Gallopamil.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Ganciclovir.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Propofol.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Propofol is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Propofol can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Propofol is combined with Degarelix.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Propofol.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Propofol.]
[J05AG04, etravirine, The metabolism of Propofol can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Propofol is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Propofol.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Propofol is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Propofol can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Propofol.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Propofol.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Propofol.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Propofol is combined with Glutethimide.]
[C05AE01, nitroglycerin, Propofol may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Propofol.]
[C02CA04, doxazosin, Propofol may decrease the antihypertensive activities of Doxazosin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Propofol.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Propofol.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Propofol.]
[C09AA09, fosinopril, Propofol may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Propofol may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Propofol is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Histrelin.]
[N05AH04, quetiapine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Propofol is combined with Iprazochrome.]
[L01CE02, irinotecan, The risk or severity of neutropenia can be increased when Propofol is combined with Irinotecan.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Propofol is combined with Allobarbital.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Propofol.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Propofol.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Propofol.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Propofol.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Propofol is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Propofol can be increased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Propofol can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Propofol is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Propofol is combined with Oxatomide.]
[C09AA04, perindopril, Propofol may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Propofol may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Propofol is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Propofol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Propofol can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, Propofol may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Propofol is combined with Prothipendyl.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Propofol can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Propofol may decrease the antihypertensive activities of Rilmenidine.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Risedronic acid.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Propofol.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Propofol.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Propofol.]
[N01AH03, sufentanil, Sufentanil may increase the sedative activities of Propofol.]
[N06AA02, imipramine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Propofol.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Propofol.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Propofol.]
[S01BC01, indomethacin, The metabolism of Propofol can be decreased when combined with Indomethacin.]
[C02CA02, indoramin, Propofol may decrease the antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Propofol is combined with Milnacipran.]
[A03AA30, piperidolate, Propofol may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Propofol is combined with Articaine.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Propofol.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Propofol.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Propofol is combined with Ramelteon.]
[R06AE01, buclizine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Propofol.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Propofol is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Propofol is combined with Alprenolol.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Propofol.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Propofol is combined with Iprindole.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Propofol.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Propofol is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Propofol.]
[P01AX06, atovaquone, The metabolism of Propofol can be decreased when combined with Atovaquone.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Propofol.]
[C09AA16, imidapril, Propofol may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Propofol.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Propofol.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Isoniazid.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Propofol is combined with Isoprenaline.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Propofol is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Propofol is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Isotretinoin.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Propofol is combined with Isoxsuprine.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Propofol.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Propofol.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Propofol.]
[L04AC07, tocilizumab, The metabolism of Propofol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Propofol is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Propofol is combined with Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Propofol.]
[J02AB02, ketoconazole, The metabolism of Propofol can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Propofol can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, The metabolism of Ketoprofen can be decreased when combined with Propofol.]
[V03AC03, deferasirox, The metabolism of Deferasirox can be decreased when combined with Propofol.]
[L04AA24, abatacept, The metabolism of Propofol can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Mizolastine.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Propofol is combined with Arbutamine.]
[N04BC09, rotigotine, Propofol may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Propofol is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Propofol is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Propofol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Amantadine.]
[C02AA05, deserpidine, Propofol may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Propofol is combined with Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Propofol is combined with Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Propofol is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Propofol.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Propofol can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Propofol.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Propofol.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Propofol.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Propofol is combined with Lofepramine.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Propofol.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Propofol.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Propofol.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Propofol.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Propofol.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Propofol.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Propofol can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be decreased when combined with Propofol.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Propofol.]
[N06AA21, maprotiline, Propofol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Propofol.]
[C02BB01, mecamylamine, Propofol may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Propofol.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Propofol is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Medazepam.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Propofol.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Propofol is combined with Melatonin.]
[N06DX01, memantine, The metabolism of Propofol can be decreased when combined with Memantine.]
[N02AB02, meperidine, Meperidine may increase the sedative activities of Propofol.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Propofol is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Propofol.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Propofol.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Propofol is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Propofol.]
[N02AX05, meptazinol, Meptazinol may increase the sedative activities of Propofol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Propofol is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Propofol is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Propofol.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Propofol.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Propofol.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Propofol is combined with Metamfetamine.]
[A03AB07, methantheline, Propofol may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Propofol is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Propofol is combined with Methaqualone.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Propofol.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Propofol.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Propofol.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Propofol is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Propofol can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Propofol.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Propofol.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Propofol is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Propofol.]
[N05AA02, methotrimeprazine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Propofol.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Propofol is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propofol.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Propofol.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Propofol.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Propofol.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Propofol.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Propofol.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Propofol.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Propofol is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Propofol.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Propofol.]
[C03BA08, metolazone, Propofol may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, Propofol may decrease the antihypertensive activities of Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Propofol is combined with Metronidazole.]
[C01BB02, mexiletine, The metabolism of Propofol can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Propofol is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Propofol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Propofol.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Propofol.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Propofol.]
[G03XB01, mifepristone, The serum concentration of Propofol can be increased when it is combined with Mifepristone.]
[C09CA03, valsartan, The metabolism of Propofol can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Propofol.]
[D11AX01, minoxidil, The metabolism of Minoxidil can be decreased when combined with Propofol.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Propofol is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Propofol is combined with Molindone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Propofol.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Propofol.]
[N06AA09, amitriptyline, Propofol may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, Morphine may increase the sedative activities of Propofol.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Propofol.]
[L04AB05, certolizumab pegol, The metabolism of Propofol can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Propofol can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Propofol.]
[L04AA06, mycophenolic acid, The metabolism of Mycophenolic acid can be decreased when combined with Propofol.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Propofol is combined with Vecuronium.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Propofol.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Raltegravir.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Propofol.]
[R03BB01, ipratropium bromide, Propofol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G03XC01, raloxifene, The metabolism of Propofol can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Propofol.]
[C07AA12, nadolol, Propofol may decrease the antihypertensive activities of Nadolol.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Propofol is combined with Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Propofol is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, Nalbuphine may increase the sedative activities of Propofol.]
[V03AB15, naloxone, The metabolism of Naloxone can be decreased when combined with Propofol.]
[N07BB04, naltrexone, Naltrexone may increase the sedative activities of Propofol.]
[L04AC03, anakinra, The metabolism of Propofol can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of CNS depression can be increased when Naphazoline is combined with Propofol.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Propofol.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Propofol.]
[A10BG01, troglitazone, The metabolism of Propofol can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Propofol is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Propofol.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Propofol.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Letrozole.]
[N01AH06, remifentanil, Remifentanil may increase the sedative activities of Propofol.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be decreased when combined with Propofol.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Propofol is combined with Levosimendan.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Propofol.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Propofol.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Propofol is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Propofol may decrease the antihypertensive activities of Telmisartan.]
[M04AA03, febuxostat, The metabolism of Febuxostat can be decreased when combined with Propofol.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Propofol.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Propofol.]
[C08CA04, nicardipine, The metabolism of Propofol can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Nicergoline is combined with Propofol.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Propofol.]
[N07BA01, nicotine, The metabolism of Propofol can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Nifedipine.]
[M02AA17, niflumic acid, The metabolism of Propofol can be decreased when combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Propofol is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Propofol may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Propofol may decrease the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Propofol.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Propofol is combined with Zaleplon.]
[N04BC05, pramipexole, Propofol may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Propofol may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Propofol is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Propofol is combined with Nomifensine.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Propofol.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Propofol.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Propofol can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Propofol.]
[R05DA07, noscapine, The metabolism of Propofol can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Propofol is combined with Nylidrin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propofol.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Propofol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Propofol can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Propofol is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Propofol is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Propofol.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Tamsulosin is combined with Propofol.]
[A14AA08, oxandrolone, The metabolism of Propofol can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Propofol is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Propofol is combined with Oxprenolol.]
[N02AA05, oxycodone, Oxycodone may increase the sedative activities of Propofol.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Propofol is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Propofol is combined with Oxymetazoline.]
[N02AA11, oxymorphone, Oxymorphone may increase the sedative activities of Propofol.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Propofol is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Propofol is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Propofol may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propofol.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Propofol.]
[M03AC01, pancuronium, Propofol may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Papaverine.]
[N05CC05, paraldehyde, Propofol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Propofol.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Propofol.]
[G04BD11, fesoterodine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Propofol is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Propofol is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Penicillamine.]
[N02AD01, pentazocine, Pentazocine may increase the sedative activities of Propofol.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Propofol.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Propofol is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Propofol is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Propofol is combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Propofol is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Propofol.]
[N02AD02, phenazocine, Phenazocine may increase the sedative activities of Propofol.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Propofol.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Propofol can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, Phenoperidine may increase the sedative activities of Propofol.]
[C04AX02, phenoxybenzamine, Propofol may decrease the antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Propofol.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Propofol.]
[V03AB36, phentolamine, Propofol may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The metabolism of Propofol can be decreased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Propofol.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Propofol.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Propofol.]
[L04AB06, golimumab, The metabolism of Propofol can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Propofol.]
[C08CX01, mibefradil, Propofol may decrease the antihypertensive activities of Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Propofol.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Propofol is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Propofol.]
[J05AE01, saquinavir, The metabolism of Propofol can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Propofol is combined with Pipotiazine.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Eprosartan.]
[A02BX03, pirenzepine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, Piritramide may increase the sedative activities of Propofol.]
[S01BC06, piroxicam, The metabolism of Propofol can be decreased when combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Grepafloxacin.]
[N02CX01, pizotyline, Propofol may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Propofol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Propofol can be decreased when combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Propofol is combined with Proxibarbal.]
[D05AX05, tazarotene, The metabolism of Propofol can be decreased when combined with Tazarotene.]
[A10BG02, rosiglitazone, The metabolism of Propofol can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Propofol.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Propofol is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Propofol can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Propofol may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The metabolism of Propofol can be decreased when combined with Ritonavir.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Pitavastatin.]
[C07AB01, practolol, Propofol may decrease the antihypertensive activities of Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Propofol is combined with Prajmaline.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Propofol is combined with Prazepam.]
[C02CA01, prazosin, Propofol may decrease the antihypertensive activities of Prazosin.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Propofol is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Propofol.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Primaquine.]
[N03AA03, primidone, The metabolism of Propofol can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Propofol can be decreased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Propofol is combined with Procainamide.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Propofol.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Propofol.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propofol.]
[N04AA04, procyclidine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Propofol can be decreased when combined with Progesterone.]
[N05AA03, promazine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The risk or severity of hypertension can be increased when Propofol is combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Propofol is combined with Propanidid.]
[A03AB05, propantheline, Propofol may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Propofol is combined with Periciazine.]
[N05CM06, propiomazine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Propofol.]
[N07XX04, sodium oxybate, Propofol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Propofol.]
[C07AA05, propranolol, Propofol may decrease the antihypertensive activities of Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Propofol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Propofol is combined with Rizatriptan.]
[B01AC09, epoprostenol, Propofol may decrease the antihypertensive activities of Epoprostenol.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Propofol.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Propofol.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Propofol is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Propofol.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Propofol is combined with Dalfampridine.]
[A03AB15, diphemanil, Propofol may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Propofol may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Propofol.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Propofol is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Propofol is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Propofol is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Propofol is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Propofol is combined with Mepyramine.]
[P01BD01, pyrimethamine, The metabolism of Propofol can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Propofol.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Propofol is combined with Quinine.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Ranitidine.]
[C02AA01, rescinnamine, Propofol may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Propofol.]
[J04AB02, rifampin, Rifampicin may increase the hypotensive activities of Propofol.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Propofol is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Propofol is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Propofol is combined with Oxitriptan.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Propofol is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Propofol is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Propofol.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Propofol is combined with Salicylic acid.]
[S01FA02, scopolamine, Propofol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The metabolism of Propofol can be increased when combined with Secobarbital.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Propofol.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Propofol is combined with Obinutuzumab.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Propofol.]
[C03DA01, spironolactone, The metabolism of Propofol can be decreased when combined with Spironolactone.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
